GAMMA Investing LLC Has $1.64 Million Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

GAMMA Investing LLC raised its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 2,959.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 67,682 shares of the biopharmaceutical company’s stock after purchasing an additional 65,470 shares during the period. GAMMA Investing LLC owned 0.06% of Catalyst Pharmaceuticals worth $1,641,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Steward Partners Investment Advisory LLC acquired a new position in shares of Catalyst Pharmaceuticals in the fourth quarter valued at about $27,000. Park Square Financial Group LLC acquired a new position in shares of Catalyst Pharmaceuticals in the fourth quarter valued at about $29,000. Farther Finance Advisors LLC grew its stake in shares of Catalyst Pharmaceuticals by 125.1% in the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock valued at $56,000 after acquiring an additional 1,495 shares in the last quarter. Quarry LP acquired a new position in shares of Catalyst Pharmaceuticals in the fourth quarter valued at about $104,000. Finally, New Vernon Capital Holdings II LLC acquired a new position in shares of Catalyst Pharmaceuticals in the fourth quarter valued at about $122,000. 79.22% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. Stephens restated an “overweight” rating and issued a $33.00 price target on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Robert W. Baird upped their price target on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an “outperform” rating in a research note on Monday, March 3rd. Wall Street Zen upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 28th. HC Wainwright reiterated a “buy” rating and set a $35.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Finally, Cantor Fitzgerald upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, June 5th. Six investment analysts have rated the stock with a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $32.83.

Insider Transactions at Catalyst Pharmaceuticals

In related news, insider Gary Ingenito sold 44,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 14th. The shares were sold at an average price of $23.63, for a total value of $1,039,720.00. Following the completion of the transaction, the insider now owns 68,873 shares in the company, valued at $1,627,468.99. This trade represents a 38.98% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Preethi Sundaram sold 1,600 shares of the firm’s stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $26.42, for a total transaction of $42,272.00. Following the completion of the transaction, the insider now owns 41,081 shares of the company’s stock, valued at approximately $1,085,360.02. This trade represents a 3.75% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 247,924 shares of company stock valued at $5,879,369. 10.40% of the stock is currently owned by insiders.

Catalyst Pharmaceuticals Stock Down 3.1%

Shares of Catalyst Pharmaceuticals stock opened at $23.53 on Friday. The company has a market capitalization of $2.87 billion, a price-to-earnings ratio of 19.94, a PEG ratio of 3.31 and a beta of 0.72. Catalyst Pharmaceuticals, Inc. has a 12-month low of $14.75 and a 12-month high of $26.58. The firm’s 50-day moving average price is $23.85 and its two-hundred day moving average price is $22.87.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.